Funding event
A target biotech raises or extends runway before your BD team knows to reach out.
For CDMO business development
Win the right programs, not more leads.
ARIA scores fresh raises, phase changes, and de-risking sponsors against your capability and open capacity, then drafts the outreach.
Buying windows ARIA watches
ARIA watches four public triggers for CDMO business development: funding, phase change, new CMC owner, and de-risking, all before they reach your CRM.
A biotech raising. A lead program changing phase. A new CMC decision-maker arriving. A sponsor reducing dependence on one geography or incumbent. Each of these sits in a filing or a registry, which is what makes it actionable rather than historical.
Phase change
A lead program advances and the sponsor starts pressure-testing manufacturing capacity.
New CMC owner
A new technical decision-maker resets vendor preference and partner selection.
Supply-chain de-risking
A sponsor starts reducing dependence on one geography or one incumbent CDMO.
Funding is public within 15 days
A Form D notice is due no later than 15 calendar days after the first sale in an offering, and the filing is public on EDGAR.
A sponsor that raises does not disclose it whenever it suits them. Under Rule 503 the notice is due no later than 15 calendar days after the first sale of securities in the offering, and it lands on EDGAR where anyone can read it. That is what makes a raise a usable trigger rather than a rumour: there is a deadline on it, the record is public, and the date the money moved is on the filing.
Source: 17 CFR 230.503. ARIA reads the primary record, not a summary of it, and links each claim back to the filing it came from.
How to rank the accounts worth working
Rank on four signals: how recently they funded, what phase the lead programme is in, whether it fits your open capacity, and who owns the decision.
Rank on four things. How recently the sponsor raised, what phase the lead programme has reached, whether the work fits capacity you actually have open, and whether the person who decides has changed. The first three tell you if there is a real need. The fourth tells you whether your existing relationship still counts.
Funding recency
A raise starts a clock. Process definition and partner selection follow the money, and the filing that discloses the round is public. Rank a sponsor that closed recently above one that closed a year ago, because the decision in the second case has usually already been made.
Development phase
Phase tells you what the sponsor needs and when. A programme moving toward the clinic needs process work now. A pre-clinical sponsor with a fresh raise needs it soon but has not scoped it. Ranking on phase stops the team spending its best hours on programmes that are years from a decision.
Capacity fit
An account only matters if you can serve it. Score each sponsor against the modality, scale, and open capacity you actually have, rather than against the work you would like to win. A high-scoring account you cannot take is a distraction, and ARIA says so rather than ranking it first.
Decision-maker change
A new CMC or technical operations owner resets vendor preference, including where you are the incumbent. Treat a leadership change as its own trigger, both on accounts you are chasing and on accounts you already hold, because it moves in both directions.
ARIA scores each account on these and shows the evidence behind the score, so the person reviewing it can disagree. Nothing is contacted without a person approving it first.
What ARIA prepares for you
For each opening, ARIA prepares a program-fit brief, capacity-timed outreach, and a CRM-ready opportunity note, sourced and staged for approval.
Every claim in that package links to the primary filing it came from, and the whole thing waits for a person to approve it before anything is sent.
Program-fit briefCapacity-timed outreachCRM opportunity note
A live deal, with the technical wedge to win it.
Your firm, your modality, your region. ARIA finds a live commercial opening, reasons the technical wedge to win it, and stages the outreach.
Reasoning trace
- Point ARIA at your firm and run. It finds a real recruiting program and prepares the read here, each step sourced.
Sourced where a source exists · held back where none does
Prepared readTriangulated
Prepared for your firm
Win the right programs
Point ARIA at your firm and run. A biotech that was just funded, the manufacturing thesis, and your first-call question compose in right here, every claim sourced.
CDMO business development
The right programs, not more leads.
ARIA scores fresh raises, phase changes, and de-risking sponsors against your capability and open capacity, then drafts the outreach.
ARIA watches
Funding event
A target biotech raises or extends runway before your BD team knows to reach out.
Phase change
A lead program advances and the sponsor starts pressure-testing manufacturing capacity.
New CMC owner
A new technical decision-maker resets vendor preference and partner selection.
Supply-chain de-risking
A sponsor starts reducing dependence on one geography or one incumbent CDMO.
ARIA prepares
Program-fit briefCapacity-timed outreachCRM opportunity note
You approve
Every claim sourced. Nothing sends on its own.
Bioprocessing equipment and consumables
Place instruments ahead of the curve.
ARIA flags the funded programs that are scaling, and surfaces competitive moves on your installed base before they cost you a reorder.
ARIA watches
Spec-in window
A process characterized on your platform tends to scale on it. The vendor is chosen when the URS is written, not at the PO.
Competitor quote
A rival appears in an installed-base account before your rep knows the account is evaluating.
Reorder window
Consumable pull-through starts to slip across sites before renewal risk shows in CRM.
Capacity expansion
A facility or suite expansion creates equipment demand before the budget is public.
ARIA prepares
Equipment-fit briefCompetitive save motionRep-ready talk track
You approve
Every claim sourced. Nothing sends on its own.
Reagent and specialty suppliers
Nobody announces they're switching.
ARIA finds where that budget sits, flags substitution risk before reorder volume drops, and prepares the account-specific reason to call.
ARIA watches
Grant cycle
A lab or diagnostics group gets funded and reagent demand moves before the team sees a purchase signal.
Spec-in window
A program in development locks its materials in early, often by Phase 1. The reagent validated now rides the program.
Substitution risk
A key account starts comparing alternative reagents before reorder volume drops.
Budget window
A lab has active spend now, while broader market demand still looks soft.
ARIA prepares
Account-specific reason to callReorder defense noteBudget-window outreach
You approve
Every claim sourced. Nothing sends on its own.
Life sciences consultants
Be the first call, not the second opinion.
ARIA tracks partner movement, buyer changes, and competitive context across the sponsors you serve, and turns it into a sourced brief or client update.
ARIA watches
Partner search
A sponsor begins comparing CDMO, tools, or supply partners before the shortlist is visible.
Portfolio movement
A company you cover changes phase, funding, buyer, or manufacturing plan.
New decision-maker
A new BD, CMC, or strategy owner changes who should be reached.
Competitive move
A competitor, partner, or supplier changes the account landscape.
ARIA prepares
Sourced partner briefAccount context readoutClient follow-up draft
You approve
Every claim sourced. Nothing sends on its own.
Questions buyers ask
- How do CDMOs find new clients?
- Most CDMO business development still runs on conferences, referrals and outbound lists. The earlier signal is public: a biotech files a Form D when it raises, registers a trial when a programme advances, and starts pressure-testing manufacturing capacity long before it issues an RFP. ARIA watches those filings and registrations continuously and prepares a sourced brief on the ones that match your capability and open capacity.
- How quickly does a biotech funding round become public?
- Fast, and on a fixed deadline. A Form D notice is due no later than 15 calendar days after the first sale of securities in the offering, and the filing appears on EDGAR where anyone can read it. That is what makes a raise usable as a trigger rather than as a rumour: there is a legal deadline attached to it, the record is public, and the date the money moved is stated on the filing itself.
- When does a biotech actually choose a CDMO?
- The decision clusters around process definition, which typically follows a financing round and precedes a public molecule or trial footprint. Reaching the technical owner during that window means helping set tech-transfer terms; arriving after it means inheriting terms someone else set.
- How should CDMO business development teams prioritise accounts?
- Rank on four inputs. How recently the sponsor raised, what phase the lead programme has reached, whether the work fits capacity you actually have open, and whether the technical decision maker has changed. The first three establish whether there is a real need and when. The fourth tells you whether an existing relationship still carries weight, which matters on accounts you already hold as well as ones you are chasing.
- What signals show a programme needs manufacturing capacity?
- A fresh raise, a phase change on a lead programme, a new CMC or technical operations hire, and supply-chain de-risking away from a single geography or incumbent. Each is publicly observable before it reaches a CRM.
- Does ARIA contact prospects on its own?
- No. It prepares the brief and drafts the outreach, then stops. Nothing sends until a person on your team approves it, and every approved action is logged and reversible.
Put ARIA on your accounts.
One workflow, your systems, your team's approval. Book a short walkthrough and see your first pass.